Back to Search
Start Over
Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment.
- Source :
-
PloS one [PLoS One] 2025 Feb 07; Vol. 20 (2), pp. e0315171. Date of Electronic Publication: 2025 Feb 07 (Print Publication: 2025). - Publication Year :
- 2025
-
Abstract
- Glioblastoma (GBM) tumors exhibit extensive genomic, epigenomic, and transcriptional diversity, with significant intratumoral heterogeneity, complicating standard treatment approaches involving radiation (RT) and the DNA-alkylating agent temozolomide (TMZ). In this study, we employed an integrative multi-omics approach, including targeted proteomics, transcriptomics, genomics, and DNA methylation profiling, to investigate the response of a representative panel of GBM patient-derived cancer stem cells (CSCs) to astrocytic differentiation and RT and TMZ treatments. Differentiated CSC progenies retained the expression of key stemness genes and survival pathways, while activating the BMP-Smad signaling pathway and upregulating extracellular matrix components. This was associated with increased resistance to TMZ, though not to RT, across all models. We identified TP53 status as a critical determinant of transcriptional response to both RT and TMZ, which was also modulated by the differentiation state and treatment modality in wildtype (wt) p53 GBM cells. Both mutant and wt p53 models exhibited significant activation of the DNA-damage associated interferon (IFN) response in CSCs and differentiated cells, implicating this pathway in the GBM response to therapy. We observed that activation of NF-κB was positively correlated with the levels of O-6-methylguanine-DNA methyltransferase (MGMT) protein, a direct DNA repair enzyme leading to TMZ resistance, regardless of MGMT promoter methylation status, further supporting the clinical potential for inhibition of NF-kB signaling in GBM treatment. Our integrative analysis of the impact of GBM cell developmental states, in the context of genomic and molecular diversity of patient-derived models, provides valuable insights for pre-clinical studies aimed at optimizing treatment strategies.<br />Competing Interests: The authors have declared that no competing interests exist.<br /> (Copyright: © 2025 Berezovsky et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Subjects :
- Humans
Cell Line, Tumor
Antineoplastic Agents, Alkylating pharmacology
Dacarbazine analogs & derivatives
Dacarbazine pharmacology
Brain Neoplasms genetics
Brain Neoplasms metabolism
Brain Neoplasms pathology
Brain Neoplasms drug therapy
DNA Methylation
Cell Differentiation drug effects
Gene Expression Regulation, Neoplastic drug effects
DNA Repair Enzymes genetics
DNA Repair Enzymes metabolism
Tumor Suppressor Proteins genetics
Tumor Suppressor Proteins metabolism
DNA Modification Methylases metabolism
DNA Modification Methylases genetics
NF-kappa B metabolism
Temozolomide pharmacology
Temozolomide therapeutic use
Glioblastoma genetics
Glioblastoma metabolism
Glioblastoma pathology
Glioblastoma drug therapy
Tumor Suppressor Protein p53 metabolism
Tumor Suppressor Protein p53 genetics
Signal Transduction drug effects
Neoplastic Stem Cells metabolism
Neoplastic Stem Cells drug effects
Neoplastic Stem Cells pathology
Interferons metabolism
Interferons pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 20
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 39919036
- Full Text :
- https://doi.org/10.1371/journal.pone.0315171